Jing Ji Guan Cha Wang·2026-02-12 01:42Group 1: Core Insights - The company has made significant progress in research and financial aspects, with the PCV24 vaccine approved for clinical trials and a forecasted turnaround to profitability in 2025 [1] Group 2: Project Advancement - On January 6, 2026, the company announced that its self-developed 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) received approval from the National Medical Products Administration to initiate clinical trials, marking a key milestone in the upgrade of its technology platform [2] Group 3: Recent Performance - On January 27, 2026, the company released a performance forecast, estimating annual revenue for 2025 to be between 1.04 billion to 1.08 billion yuan, representing a year-on-year growth of 22.88% to 27.61%; net profit attributable to shareholders is expected to be between 24.5 million to 29 million yuan, indicating a turnaround to profitability [3] Group 4: Business and Technical Development - The DTP vaccine has completed Phase III clinical trials and is expected to receive approval in the first half of 2026; the company has obtained halal certification for its MenACWY vaccine in Indonesia and is deepening overseas clinical collaborations, focusing on emerging markets in Southeast Asia and the Middle East; the 13-valent pneumococcal conjugate vaccine is set to launch in September 2025, with accelerated market access [4]